January 4, 2019 05:25 AM EST
Pharma

Sanofi sharp­ens fo­cus on mR­NA for can­cer with eq­ui­ty in­vest­ment in Ger­many's BioN­Tech

Natalie Grover

Reporter

Sanofi is beef­ing up its bet on mes­sen­ger RNA tech­nol­o­gy. Hav­ing al­ready set up al­liances with Ron Re­naud’s Trans­late Bio, and Ger­many’s Cure­Vac and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

A service from the Financial Times